Olanzapine for the Prevention of Postoperative Nausea and Vomiting

Olanzapine for the Prevention of Postoperative Nausea and Vomiting After Laparoscopic Surgery in High-risk Patients: A Randomized Controlled Trial

Nausea and vomiting (PONV) remain a common problem in surgical units. Even after two or three prophylactic antiemetic interventions, patients with all four of the Apfel risk factors for PONV have an estimated 30 to 40% chance of suffering PONV. Olanzapine as an antiemetic represents a new use of an antipsychotic drug.

Aim of the Research, to compare the effects of oral 10 and 5 mg Olanzapine for the Prevention of Postoperative Nausea and Vomiting

Inclusion Criteria:

• ASA I and II patients
• undergoing ambulatory laparoscopic gynecologic surgery with general anesthesia
• patients have at least two of the four Apfel risk factors for PONV2
• Lack of history of psychiatric and psychotic illnesses.

Exclusion Criteria:

• ASA III and ≥ IV patients
• Psychological diseases
• History of chemotherapy
• have a pre-existing vestibular disorder or history of dizziness or preexisting nausea or vomiting in the 24 h before surgery, or were being treated with regular antiemetic therapy including systemic corticosteroids.